Triveni Bio clinical trials
Triveni Bio is the lead sponsor of 3 current clinical trials in our USA, Canada, Poland, Czechia and EU (CTIS) registers. 1 is recruiting patients now. All registered phases are Phase 2. The most-studied condition is Atopic Dermatitis.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Triveni Bio
2 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study Evaluating TRIV-573 in Atopic Dermatitis
NCT07782333 · ClinicalTrials.gov ↗ · Atopic Dermatitis
|
Phase 2 | Recruiting | 2026-09 | USA, Canada |
|
A Study Evaluating TRIV-509 in Atopic Dermatitis
NCT07167758 · Atopic Dermatitis
|
Phase 2 | Active, closed | 2025-08 | USA, Poland, Czechia, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Triveni Bio in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System with Triveni Bio as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis
2026-526485-25-00 · CTIS ↗ · Skin and Connective Tissue Diseases
|
Phase 2 | Authorised | Czechia, Poland |
Conditions in Triveni Bio trials
1 conditionBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Canada | 2 | 1 |
| Clinical trials in Poland | 1 | 0 |
| Clinical trials in Czechia | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Atopic Dermatitis
Sponsors with the most current trials registered for this condition.
Questions about Triveni Bio trials
How many clinical trials does Triveni Bio sponsor?
Triveni Bio is the lead sponsor of 2 current trials on ClinicalTrials.gov in our USA, Canada, Poland and Czechia registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 29 October 2026. Completed and withdrawn studies are not counted.
Are Triveni Bio trials recruiting?
Yes. 1 of its 2 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 29 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.